This is the authors' abstract. We don't add key points for this paper.
Ziel/Aim: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are a rare disease [ 1 ] [ 2 ]. Current guidelines recommend treatment with somatostatin receptor (SSTR) targeting radioligand therapy (RLT) [ 1 ] [ 3 ]. SSTR-RLT is available as 177 Lu-radiolabeled somatostatin analogues locally compounded by hospitals (non-licensed product) and as EMA approved product with standardized formulation and application. Limited real-world data exist on the German care situation with SSTR-RLT. Methodik/Methods: This non-interventional study was conducted via retrospective chart review of patient data from 7 medical centers. Data of adult GEP-NET patients in Germany receiving their first cycle of primary SSTR-RLT between July 2020 – June 2021 were included. The analyses focused on patient demographics, medical history and RLT treatment patterns. Ergebnisse/Results: Data of 117 patients were included, 60.7% were male, aged between 51-75 years (72.6%) with a progressive tumor (87.2%). RLT was mainly received as 2nd line therapy (77.8%). Mean time from initial diagnosis to initiation of primary RLT was ~4 years. RLT-administration mostly corresponded to guideline and treatment recommendations [ 1 ] [ 3 ]. 45 patients (38.5%) received a non-licensed preparation, 63 (53.8%) were treated with the approved product and 9 (7.7%) switched product during the treatment period. Results indicate that the licensed product was well tolerated and corresponded to the established safety profile [ 4 ]. Imaging data of the licensed product show a disease control rate of 76.2%. Schlussfolgerungen/Conclusion: The results of the study indicate that SSTR-RLT is used in accordance with guideline recommendations [ 1 ] [ 3 ]. The results support the relevance of SSTR-RLT in routine clinical care of GEP-NET patients in Germany with good tolerability as part of a standardized regimen following the SmPC of the approved medicinal product. Real-world data and new phase III efficacy and safety data (NETTER-2) may further increase the clinical relevance of licensed SSTR-RLT in treating GEP-NET patients. [ 5 ] Publication History Article published online: 12 March 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Herrmann et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: